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Abstract
We present a case of locally advanced rectal cancer with initial optimal local control after
neoadjuvant concurrent chemoradiotherapy followed by surgery; early liver recurrence then
occurred and was treated again with curative intent with neoadjuvant combination chemotherapy
followed by liver surgery. We reflect on this difficult problem and discuss relevant topics to this
case report.
Clinical case
A male of 56 years of age with clinical history of hyperuri-
cemia and gout was hospitalised because of rectal bleed-
ing. His symptoms had started two months prior, and he
had been diagnosed with haemorrhoids.
On admission, he had mild anemia. Blood chemistry and
coagulation were normal. A full colonoscopy was per-
formed, which detected a 5 cm long, non stenosing rectal
tumour, starting after the dentate line, in addition to a sig-
moid polyp. Biopsies revealed a rectal adenocarcinoma
and a non dysplastic adenomatous polyp in sigmoid
colon. Staging studies were completed with tumour mark-
ers (CEA and CA 19.9) measurement, echoendoscopy and
a thoracic-abdominal-pelvic CT. Tumour markers values
were within normal range, echoendoscopy showed a 6 cm
long uT3N0 rectal cancer, and CT detected an eccentric
thickening of the rectal wall, compatible with a rectal can-
cer with no lymph node or visceral involvement. Final
diagnosis was a rectal adenocarcinoma located in the mid-
dle-inferior thirds, clinical stage T3 N0 M0 (Figures. 1, 2).
His clinical case was discussed shortly after in our Diges-
tive Tumours Commitee, and neoadjuvant combined
chemoradiotherapy followed by surgery were planned.
The patient received capecitabine 900 mg/m2/12h d1-5/
7d concurrent with radiotherapy, 45 Gy (180 cGy/d) [1].
Treatment was generally well tolerated, with moderate
cystitis and mild epithelitis as major adverse effects. Reas-
sessment after neoadjuvant treatment showed neither
blood analysis abnormalities, nor CT suspicion of resid-
ual disease (Figure. 3).
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Fifty-three days after completing chemoradiotherapy
patient underwent surgery. An abdominoperineal (AP)
resection, including with mesorectal excision (TME), was
performed with no surgical complications. Subsequent
pathological analysis revealed a complete pathological
response (TRG 1) [2] (Figure. 4); with none out of four
isolated lymph nodes involved; mesorectal excision was
complete and the circumferential margin was greater than
1 cm.
Five weeks after surgery the patient was again referred to
Clinical Oncology, were, once we had confirmed the
absence of disease by blood analysis and imaging, adju-
vant treatment was planned. Adjuvant fluorouracil-based
chemotherapy was then administered in order to com-
plete a total of six months neoadjuvant and adjuvant
treatment [3,4]. Thoracic-abdominal-pelvic CT performed
shortly after completing adjuvant chemotherapy, and this
showed only surgical changes; colonoscopy through the
end colostomy was normal, and blood analysis, including
CEA and CA 19.9 levels, were also normal. The patient
entered into our three-monthly periodic follow-up pro-
gram [5].
Eighteen months after initial diagnosis, the patient was
asymptomatic. Programmed review detected increased
CEA value (25 u/ml, normal value < 10) associated with a
left lobe liver metastatic lesion of size 6 cms. in thoracic-
abdominal-pelvic CT (Figure. 5). PET scan performed
showed no other metastatic sites [6]. The patient received
neoadjuvant chemotherapy with combination of intrave-
nous fluorouracil c.i., oxaliplatin [7]. After completing
four cycles, revaluation tests showed normalisation of
CEA levels and complete disappearance of the liver lesion
(Figure. 6). Patient was then referred to surgery. He subse-
quently had a liver trisegmentectomy, involving segments
1, 2 and 3 (Figure. 7). Pathological analysis revealed a 1
cm residual focus of metastatic non-expressing EGFR
colorectal adenocarcinoma. Recently, six weeks after liver
surgery, and in the absence of residual disease, patient has
started adjuvant chemotherapy with FOLFOX-4, planned
to last for four months.
Discussion
Concurrent preoperative chemoradiotherapy has proven
superior to other treatment strategies against locally
advanced rectal cancer. Neoadjuvant combined treatment
reduces local relapse compared to adjuvant combined
treatment [8] and exclusive preoperative radiotherapy
[9,10]. Nevertheless, this benefit not always means an
CT reassessment of primary rectal tumour after neoadjuvant  treatment Figure 3
CT reassessment of primary rectal tumour after neoadjuvant 
treatment.
CT at initial diagnosis showing absence of liver involvement Figure 2
CT at initial diagnosis showing absence of liver involvement.
CT at diagnosis showing an eccentric thickening of the rectal  wall, compatible with a rectal cancer with no lymph node or  visceral involvement Figure 1
CT at diagnosis showing an eccentric thickening of the rectal 
wall, compatible with a rectal cancer with no lymph node or 
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increase in terms of overall survival. Inadequate doses of
chemotherapy, with radiosensitizer but without systemic
effect, and sub-optimal chemotherapy strategies may both
well explain this paradox. The clinical case previously
commented is an example of what may occur in early
stage rectal cancer patients. Far from presenting local
relapse, distant metastases may occur, and is being seen
with increasing frequency.
Submucosal fibrotic scarring Figure 4
Submucosal fibrotic scarring. Detail of vertical vessels (1). Detail of radiotherapy induced obliterant vasculitis with foamy histi-
ocytes in intimae (2).
Left lobe liver metastatic lesion of size 6 cms Figure 5
Left lobe liver metastatic lesion of size 6 cms. in thoracic-
abdominal-pelvic CT performed in February 2007.
Clinical complete response assesed in thoracic-abdoninal-pel- vic CT performed in May 2007, after neoadjuvant systemic  chemotherapy Figure 6
Clinical complete response assesed in thoracic-abdoninal-pel-
vic CT performed in May 2007, after neoadjuvant systemic 
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By combined neoadjuvant chemoradiotherapy, followed
by surgery including total mesorectal excision, it is clear
that very good local control of rectal cancer can be
achieved, with five-year local relapse rates of 6–8% [8-10].
This very good local control rate may be optimized when
effectiveness of neoadjuvant treatment is demonstrated
after surgery of regressive disease, and adjuvant chemo-
therapy with a similar regimen to that previously used in
the neoadjuvant setting is completed [4]. The challenge
on the horizon is then to reduce distant relapse, in order
to prolong overall survival. The best way to accomplish
this goal might be to divide preoperative treatment into
two steps: neoadjuvant combined chemotherapy fol-
lowed by neoadjuvant concurrent chemoradiotherapy.
First step would include only combined chemotherapy, so
that optimal doses and regimens with demonstrated sys-
temic effect could be safely administered, within an
attempt to control micrometastatic systemic disease. In a
second stage treatment would focus on local control by
concurrent administration of radiotherapy and chemo-
therapy, this time using adjusted doses in order to achieve
synergistic effect avoiding excessive toxicity. This
approach has already been partially succesfully tested in
phase II clinical trials [11], and is yet to be confirmed in
on course phase III clinical trials.
Fortunately, continuous investigation-based advances
have made potentially curative treatment strategies avail-
able to patients, as the one here reported, even in the case
of distant relapse, and when no evidence of extrahepatic
disease is found [6]. Combination chemotherapy with
fluroropyrimidines (fluorouracil or capecitabine), oxali-
platin, or irinotecan, and-more recently-bevacizumab or
cetuximab, has improved response rates, progression-free
survival and, in three trials, overall survival [12-15]. Com-
binations of three of these drugs have achieved best
response rates so far in metastatic colorectal cancer, and so
should be advised in the neoadjuvant setting of poten-
tially resectable liver only metastatic disease [12-15].
Recent results favour, in case of resectable or potentially
resectable liver only metastatic disease, combination sys-
temic perioperative treatment in order to achieve best
overall survival [7,16,17]. Eventhough complete clinical
response to neoadjuvant chemotherapy may be achieved,
resection of metastatic sites, when possible, is mandatory
[18].
In conclusion, although recent improvements in treat-
ment of advanced colorectal cancer make it possible to
offer certain subsets of patients potential healing even in
case of relapse after early disease, future treatment strate-
gies in locally advanced rectal cancer need to focus not
only in achieving optimal local control but in avoiding
distant failure.
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